1. A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells
- Author
-
Elisabetta Barresi, Caterina Baldanzi, Marta Roncetti, Michele Roggia, Emma Baglini, Irene Lepori, Marianna Vitiello, Silvia Salerno, Lorena Tedeschi, Federico Da Settimo, Sandro Cosconati, Laura Poliseno, Sabrina Taliani, Barresi, Elisabetta, Baldanzi, Caterina, Roncetti, Marta, Roggia, Michele, Baglini, Emma, Lepori, Irene, Vitiello, Marianna, Salerno, Silvia, Tedeschi, Lorena, Da Settimo, Federico, Cosconati, Sandro, Poliseno, Laura, and Taliani, Sabrina
- Subjects
BRAF(V600E) ,Pharmacology ,Fluorescent probe ,Vemurafenib ,Organic Chemistry ,Drug Discovery ,General Medicine ,Cyanine-5 ,Hairy cell leukemia ,Melanoma - Abstract
BRAF represents one of the most frequently mutated protein kinase genes and BRAFV600E mutation may be found in many types of cancer, including hairy cell leukemia (HCL), anaplastic thyroid cancer (ATC), colorectal cancer and melanoma. Herein, a fluorescent probe, based on the structure of the highly specific BRAFV600E inhibitor Vemurafenib (Vem, 1) and featuring the NIR fluorophore cyanine-5 (Cy5), was straightforwardly synthesized and characterized (Vem-L-Cy5, 3), showing promising spectroscopic properties. Biological validation in BRAFV600E-mutated cancer cells evidenced the ability of 3 to penetrate inside the cells, specifically binding to its elective target BRAFV600E with high affinity, and inhibiting MEK phosphorylation and cell growth with a potency comparable to that of native Vem 1. Taken together, these data highlight Vem-L-Cy5 3 as a useful tool to probe BRAFV600E mutation in cancer cells, and suitable to acquire precious insights for future developments of more informed BRAF inhibitors-centered therapeutic strategies.
- Published
- 2023
- Full Text
- View/download PDF